GO
Loading...

Eli Lilly and Co

More

  • Lilly Says Lechleiter to Succeed Taurel as CEO Tuesday, 18 Dec 2007 | 8:37 AM ET

    Eli Lilly Tuesday said Sidney Taurel, the drugmaker's long-time chief executive officer, will retire on March 31 and will be succeeded by Chief Operating Officer John Lechleiter.

  • Amgen: Stock "Ailing" From Many Sides It Seems Friday, 7 Dec 2007 | 2:24 PM ET

    Earlier this week I blogged about Amgen's negative test results for its anemia drug Aranesp in breast cancer. The studies showed the drug may have caused tumors to grow and death. This morning it almost seems like there's a delayed market reaction.

  • Big Pharma, Big Problems Friday, 7 Dec 2007 | 12:43 PM ET

    The drug industry could face plunging sales as patents on some blockbusters are set to expire, according to Thursday’s WSJ. Can you trade the Journal’s grim prognosis?

  • Lilly 2008 Profit Forecast Eclipses Expectations Thursday, 6 Dec 2007 | 2:08 PM ET
    Eli Lilly

    Eli Lilly Thursday forecast 2008 earnings above Wall Street expectations and said it remained on track to seek U.S. approval this month for prasugrel, a blood clot preventer, which posted mixed results in a recent large clinical trial.

  • BMY CEO Cornelius: You Should Have Gotten A Flu Shot Wednesday, 5 Dec 2007 | 2:36 PM ET
    CEO Jim Cornelius

    Regular blog readers are well aware of my relentless pursuit of big CEO interviews. So, I wanted to give the backstory to a surprising CEO cancellation of a previously scheduled and confirmed interview today by Bristol-Myers Squibb. A few weeks ago, my producer Ruth and I got tentative confirmation from a Bristol spokesman that the relatively new CEO Jim Cornelius would finally do his first TV interview since taking over the company last year.

  • Big Pharma Events: The Pre-Holiday Crunch Wednesday, 5 Dec 2007 | 10:50 AM ET

    I don't know how they all got clustered together--maybe so many of the major pharmaceutical companies meet with Wall Street in early December so everyone can then take off on long vacations--but my hands are full with three big pharma events in as many days. Yesterday, Merck put out guidance.

  • Name Tags, Bad Coffee and Trades Friday, 30 Nov 2007 | 7:01 PM ET

    With little earnings news, analyst conferences appear to be dictating the market. What's the trade heading into next week?

  • Drugs On The Street Wednesday, 28 Nov 2007 | 7:13 PM ET

    Pfizer (PFE) hit a 52-week low while Merck (MRK) sprinted to a 4 year high, both ahead of analyst meetings. What’s the trade as drug makers get a physical from Wall Street?

  • Pharma CEO's: Getting Them To Talk To Me Wednesday, 28 Nov 2007 | 3:40 PM ET

    Regarding my post from yesterday about Lilly CEO Sidney Taurel, a spokesman  left me a voicemail this morning to say it has no intention of backing out of the interview next week. I've got a tentative commitment from Bristol-Myers Squibb to interview its new CEO Jim Cornelius for the first time at that company's analyst meeting next week.

  • Sidney Taurel

    If you arrive for work at CNBC headquarters early enough you can pick up a copy of "The Wall Street Journal" at the lobby desk when you walk in. Today, I grabbed mine and set it down on my desk while I logged onto my computer and cleaned out my inbox.

  • Merck & the Media Monday, 26 Nov 2007 | 11:15 AM ET

    So, does this mean I'm gonna get scooped by Reuters on Merck stories? I'm just kidding, but that was one of my reactions when I saw the press release this morning from Merck announcing that it's putting the CEO of Reuters, Tom Glocer, on its Board of Directors. The head of a financial data and news company on the Board of a major drug company. Very interesting.

  • Investors Want A New Drug Wednesday, 21 Nov 2007 | 6:51 PM ET

    Big drug companies might not be so defensive anymore. Here’s why.

  • It didn't take long for Japan's Takeda Pharmaceuticals, which trades on the Tokyo exchange, to try to capitalize on the new safety warning for GlaxoSmithKline's diabetes drug Avandia. Last week the FDA slapped a so-called "Black Box"--the agency's most severe warning--on the Avandia label advising patients and doctors about the potential heart attack and stroke risk that's been the subject of so much controversy over the past several months.

  • If the writer's strike has you looking for alternatives to insomnia-fighting late-night TV shows, then Pfizer may have just what the doctor ordered. Tune into the company's web cast for investors and analysts at 11 p.m. Eastern Daylight Savings Time on Thursday, November 29th. If you don't believe me check out the press release on the Pfizer web site. The world's biggest drug company is taking its show on the road to Hong Kong.

  • Pharma Stocks To Watch On Monday (And My Time Off) Sunday, 4 Nov 2007 | 12:57 PM ET

    I'm taking some much needed time off for a couple of weeks. Actually, our scheduling guru at CNBC, Alex Crippen, told me if I don't use all of the days I've accumulated by the end of next month, I'll lose them. I consider myself a hard worker, but I'm not that generous. So, off I go.

  • Eli Lilly: Will They Get Lucky With 'One A Day' Cialis? Wednesday, 31 Oct 2007 | 3:36 PM ET
    Eli Lilly

    Today's the day Eli Lilly was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on boa

  • Amylin's Once A Week Byetta: Good Is Not Enough Wednesday, 31 Oct 2007 | 12:21 PM ET
    Byetta Needle

    This morning Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the highly anticipated test results on their once-a-week, Type 2 diabetes drug. One analyst recently called this the most important biotech data of the second half of this year. Many expect the drug to become a multi-billion dollar blockbuster.

  • Stocks Edge Lower After Seesaw Day Thursday, 25 Oct 2007 | 4:26 PM ET

    Stocks finished near even Thursday as Wall Street endured another topsy-turvy session, with rumors – of more subprime trouble and a Fed rate cut – proving just as influential on the markets as a handful of economic and earnings reports.

  • Lilly Stock Drops on Halted Clot Drug Trials Thursday, 25 Oct 2007 | 11:51 AM ET

    Shares of Eli Lilly fell more than 6 percent on Thursday, after the drugmaker halted two small trials of blood clot preventer prasugrel, the company's most important experimental drug.

  • Eli Lilly: "Bloom" Is Off The Pipeline Thursday, 25 Oct 2007 | 11:43 AM ET
    Eli Lilly

    If the stock closes down at least 4.46% today (as I write this it is off nearly 7%) Eli Lilly will suffer its worst one-day loss in more than four years, according to our resident statistical expert Robert Hum. If it were to close off more than 7.79%, Hum says it would be the stock's biggest one-day fall since Oct. 23, 2002--almost five years to the day.